News coverage about Aeglea BioTherapeutics (NASDAQ:AGLE) has trended somewhat positive recently, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aeglea BioTherapeutics earned a daily sentiment score of 0.22 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 47.7830529171558 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Shares of Aeglea BioTherapeutics (NASDAQ:AGLE) traded down $0.08 during trading on Friday, hitting $4.27. 18,050 shares of the stock traded hands, compared to its average volume of 52,279. Aeglea BioTherapeutics has a twelve month low of $2.81 and a twelve month high of $8.14.

Aeglea BioTherapeutics (NASDAQ:AGLE) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.07. The business had revenue of $1.26 million for the quarter. Aeglea BioTherapeutics had a negative net margin of 527.99% and a negative return on equity of 44.05%. research analysts expect that Aeglea BioTherapeutics will post -1.97 EPS for the current year.

Separately, Zacks Investment Research upgraded shares of Aeglea BioTherapeutics from a “hold” rating to a “buy” rating and set a $5.50 price objective on the stock in a research note on Friday, November 10th.

ILLEGAL ACTIVITY WARNING: “Aeglea BioTherapeutics (AGLE) Given News Impact Score of 0.22” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at

About Aeglea BioTherapeutics

Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.

Insider Buying and Selling by Quarter for Aeglea BioTherapeutics (NASDAQ:AGLE)

Receive News & Ratings for Aeglea BioTherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.